Gebasaxturev

DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.

Neoadjuvant pembrolizumab, alone or combined with vibostolimab or gebasaxturev, demonstrated a manageable safety profile in stage IIIB-D melanoma patients, with 95% experiencing at least one adverse event.

The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy.

Updated data from the NADINA trial demonstrates that neoadjuvant ipilimumab plus nivolumab significantly improves event-free and distant metastasis-free survival compared to adjuvant nivolumab in resectable stage III melanoma.

Merck & Co's $394 million acquisition of Viralytics signals growing interest in oncolytic viruses as potential enhancers for cancer immunotherapy treatments.